Versant Venture Management 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
Clovis Oncology, Inc.	Common Stock	189464100	647,798	101,855	SH		OTR		0	101,855	0
CymaBay Therapeutics, Inc.	Common Stock	23257D103	804,754	543,753	SH		OTR		0	543,753	0
Gritstone Oncology, Inc.	Common Stock	39868T105	18,059,047	3,102,929	SH		OTR		0	3,102,929	0
Second Sight Medical Products, Inc.	Common Stock	81362J100	558,635	561,612	SH		OTR		0	4,492,975	0
Ocular Therapeutix, Inc.	Common Stock	67576A100	10,966,151	2,215,384	SH		OTR		0	2,215,384	0
CRISPR Therapeutics AG	Common Stock	H17182108	177,224,616	4,205,615	SH		OTR		0	4,205,615	0
Veracyte, Inc.	Common Stock	92337F107	29,303,444	1,205,407	SH		OTR		0	1,205,407	0
Adverum Biotechnologies, Inc.	Common Stock	00773U108	69,056,636	7,068,233	SH		OTR		0	7,068,233	0
Akero Therapeutics, Inc.	Common Stock	00973Y108	58,015,326	2,736,572	SH		OTR		0	2,736,572	0